Mirtazapine Rosemont Pharmaceuticals (Mirtazapine)

Mirtazapine increases neurotransmission by blocking presynaptic α2‑adrenergic receptors, which raises norepinephrine release, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity while reducing certain serotonin‑mediated side effects.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors, mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. Its side‑effect spectrum differs, and it may be preferred when those specific effects are clinically desirable.

Mirtazapine Rosemont Pharmaceuticals should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability.

Mirtazapine is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, hyponatraemia, and the emergence or worsening of suicidal thoughts, especially during early treatment or dose changes. Patients should be monitored closely for these rare but critical adverse events.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to the drug. Caution is advised for individuals with severe hepatic impairment, uncontrolled epilepsy, or a history of severe allergic reactions.